California voters approved Proposition 38, which authorizes $8.4 billion in bond borrowing for immunology research as federal science funding faces cuts and delays. The plan divides the money: half will fund grants open to researchers at different institutions, while the other half is reserved for a facility described in the measure but not named. Its detailed requirements appear to point to the California Institute for Immunology and Immunotherapy, a nonprofit affiliated with UCLA. The institute was co-founded and heavily funded by billionaire surgeon and inventor Gary Michelson, who spent $66 million supporting the ballot campaign. Supporters say the investment will build a research hub capable of advancing treatments for cancer, Alzheimer’s and other diseases, and that revenue from resulting therapies will help repay the bonds.
Critics argue the measure gives one private institution an unfair advantage and may violate the state Constitution’s restriction on initiatives assigning functions to a specific corporation, even if it is identified indirectly. They also question whether future drug revenues can cover borrowing costs, potentially leaving taxpayers responsible, and doubt that a promised discount for Californians will be easy to deliver through the health care system. Supporters point to the potential for major scientific breakthroughs; critics note that an earlier California bond-funded biomedical initiative has produced only one approved treatment in two decades. The dispute is sharpened by the campaign’s lopsided financing and the institute’s close connection to Michelson, whose previous philanthropy and state partnerships helped establish it.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.